Görges M, West N, Deyell R, Winton P, Cheung W, Lauder G. Dexmedetomidine and hydromorphone: a novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children. Pediatr Blood Cancer. 2015;62:29-34 pubmed publisher

Cheng M, Ahmed M, Xu H, Cheung N. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. Int J Cancer. 2015;136:476-86 pubmed publisher

Hong S, Ostaszewski B, Yang T, O Malley T, Jin M, Yanagisawa K, et al. Soluble A? oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron. 2014;82:308-19 pubmed publisher

Cheung N, Cheung I, Kramer K, Modak S, Kuk D, Pandit Taskar N, et al. Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. Int J Cancer. 2014;135:2199-205 pubmed publisher

Matarrese P, Garofalo T, Manganelli V, Gambardella L, Marconi M, Grasso M, et al. Evidence for the involvement of GD3 ganglioside in autophagosome formation and maturation. Autophagy. 2014;10:750-65 pubmed publisher

Ahmed M, Cheung N. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 2014;588:288-97 pubmed publisher

Siebert N, Seidel D, Eger C, Brackrock D, Reker D, Schmidt M, et al. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab. J Immunol Methods. 2013;398-399:51-9 pubmed publisher

Kroesen M, Nierkens S, Ansems M, Wassink M, Orentas R, Boon L, et al. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma. Int J Cancer. 2014;134:1335-45 pubmed publisher

Horwacik I, Durbas M, Boratyn E, Wegrzyn P, Rokita H. Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells. Cancer Lett. 2013;341:248-64 pubmed publisher

Druĭ A, Tsaur G, Popov A, Tuponogov S, Shorikov E, Tsvirenko S, et al. [The TH, ELAVL4 and GD2 gene expression as diagnostic markers of bone marrow lesions in patients with neuroblastoma]. Vopr Onkol. 2012;58:514-20 pubmed

Lode H, Schmidt M, Seidel D, Huebener N, Brackrock D, Bleeke M, et al. Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response. Cancer Immunol Immunother. 2013;62:999-1010 pubmed publisher

Cochonneau D, Terme M, Michaud A, Dorvillius M, Gautier N, Frikeche J, et al. Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo. Cancer Lett. 2013;333:194-204 pubmed publisher

Vincent M, Bessard A, Cochonneau D, Teppaz G, Solé V, Maillasson M, et al. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency. Int J Cancer. 2013;133:757-65 pubmed publisher

Sakai D, Nakamura Y, Nakai T, Mishima T, Kato S, Grad S, et al. Exhaustion of nucleus pulposus progenitor cells with ageing and degeneration of the intervertebral disc. Nat Commun. 2012;3:1264 pubmed publisher

Alderson K, Luangrath M, Elsenheimer M, Gillies S, Navid F, Rakhmilevich A, et al. Enhancement of the anti-melanoma response of Hu14.18K322A by ?CD40 + CpG. Cancer Immunol Immunother. 2013;62:665-75 pubmed publisher

Ruf P, Schäfer B, Eissler N, Mocikat R, Hess J, Plöscher M, et al. Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model. J Transl Med. 2012;10:219 pubmed publisher

Shibina A, Seidel D, Somanchi S, Lee D, Stermann A, Maurer B, et al. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. J Mol Med (Berl). 2013;91:459-72 pubmed publisher

Tong W, Sprules T, Gehring K, Saragovi H. Rational design of peptide ligands against a glycolipid by NMR studies. Methods Mol Biol. 2012;928:39-52 pubmed publisher

Tarek N, Le Luduec J, Gallagher M, Zheng J, Venstrom J, Chamberlain E, et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest. 2012;122:3260-70 pubmed publisher

Shen M, Gong F, Pang P, Zhu K, Meng X, Wu C, et al. An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma. Int J Nanomedicine. 2012;7:3319-32 pubmed publisher

Eissler N, Ruf P, Mysliwietz J, Lindhofer H, Mocikat R. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res. 2012;72:3958-66 pubmed publisher

Yankelevich M, Kondadasula S, Thakur A, Buck S, Cheung N, Lum L. Anti-CD3?×?anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer. 2012;59:1198-205 pubmed publisher

Tivnan A, Orr W, Gubala V, Nooney R, Williams D, McDonagh C, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS ONE. 2012;7:e38129 pubmed publisher

Shibuya H, Hamamura K, Hotta H, Matsumoto Y, Nishida Y, Hattori H, et al. Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci. 2012;103:1656-64 pubmed publisher

Mast C. [Nursing care for a child with recurrent neuroblastoma treated with immunotherapy]. Kinderkrankenschwester. 2012;31:142-4 pubmed

Matthay K, George R, Yu A. Promising therapeutic targets in neuroblastoma. Clin Cancer Res. 2012;18:2740-53 pubmed publisher

Battula V, Shi Y, Evans K, Wang R, Spaeth E, Jacamo R, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest. 2012;122:2066-78 pubmed publisher

Ziebarth A, Felder M, Harter J, Connor J. Uterine leiomyosarcoma diffusely express disialoganglioside GD2 and bind the therapeutic immunocytokine 14.18-IL2: implications for immunotherapy. Cancer Immunol Immunother. 2012;61:1149-53 pubmed publisher

Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, et al. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer. 2012;106:1123-33 pubmed publisher

Cazet A, Bobowski M, Rombouts Y, Lefebvre J, Steenackers A, Popa I, et al. The ganglioside G(D2) induces the constitutive activation of c-Met in MDA-MB-231 breast cancer cells expressing the G(D3) synthase. Glycobiology. 2012;22:806-16 pubmed publisher

Louis C, Savoldo B, Dotti G, Pule M, Yvon E, Myers G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118:6050-6 pubmed publisher

Alvarez Rueda N, Desselle A, Cochonneau D, Chaumette T, Clémenceau B, Leprieur S, et al. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity. PLoS ONE. 2011;6:e25220 pubmed publisher

Heimburg Molinaro J, Lum M, Vijay G, Jain M, Almogren A, Rittenhouse Olson K. Cancer vaccines and carbohydrate epitopes. Vaccine. 2011;29:8802-26 pubmed publisher

Acosta S, Mayol G, Rodriguez E, Lavarino C, De Preter K, Kumps C, et al. Identification of tumoral glial precursor cells in neuroblastoma. Cancer Lett. 2011;312:73-81 pubmed publisher

Soman G, Yang X, Jiang H, Giardina S, Mitra G. Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA. J Immunol Methods. 2011;373:181-91 pubmed publisher

Pichla S, Murali R, Burnett R. The crystal structure of a Fab fragment to the melanoma-associated GD2 ganglioside. J Struct Biol. 1997;119:6-16 pubmed